{"organizations": [], "uuid": "eb51a83bd765446c20c3ecf98556c70bc0c7d52d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/27/business-wire-the-medicines-company-announces-chief-financial-officer-transition.html", "country": "US", "domain_rank": 767, "title": "The Medicines Company Announces Chief Financial Officer Transition", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T04:05:00.000+03:00", "replies_count": 0, "uuid": "eb51a83bd765446c20c3ecf98556c70bc0c7d52d"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/27/business-wire-the-medicines-company-announces-chief-financial-officer-transition.html", "ord_in_thread": 0, "title": "The Medicines Company Announces Chief Financial Officer Transition", "locations": [], "entities": {"persons": [{"name": "christopher visioli", "sentiment": "none"}, {"name": "william b. o’connor", "sentiment": "none"}, {"name": "chris", "sentiment": "none"}, {"name": "clive meanwell", "sentiment": "none"}, {"name": "meanwell", "sentiment": "none"}, {"name": "visioli", "sentiment": "none"}, {"name": "o’connor", "sentiment": "none"}], "locations": [{"name": "n.j.", "sentiment": "none"}, {"name": "parsippany", "sentiment": "none"}], "organizations": [{"name": "medicines company", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately. Mr. Visioli succeeds William B. O’Connor, who is retiring from the Company after serving as Chief Accounting Officer and then Chief Financial Officer for a total of 13 years. Mr. O’Connor will remain with the Company as an advisor through 2018, assisting Mr. Visioli in transition and completing the close-out of the Company’s non-core businesses and products. Mr. Visioli will report directly to Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company.\n“Chris brings extensive leadership experience and broad operational expertise developed over a long and successful career at The Medicines Company,” Dr. Meanwell said. “Chris will play an important role as we continue to successfully execute on our strategic plan. I know that the Company will benefit from his expertise, insight and experience, and I and the rest of the Company’s Board of Directors look forward to working with him. In addition, I would like to personally thank Bill for his contributions to the Company over more than a decade of successful service. Bill will continue to serve as an advisor as we wind down our legacy businesses, and I wish him luck in his retirement upon conclusion of this important work.”\nMr. Visioli previously served as Senior Vice President, Financial Strategy, of the Company from January 2015 to March 2018, and Vice President, Cardiovascular Care, from January 2013 to December 2014. Mr. Visioli joined the Company in June 2003 and has served in a variety of leadership roles in the organization, including finance, business development, investor relations, strategy, planning, and business leadership of the Cardiovascular Care business unit. Prior to joining the Company, Mr. Visioli was a management consultant at Ernst & Young. Mr. Visioli holds a Bachelor’s Degree in electrical engineering from Cornell University and an M.B.A. from Columbia Business School.\nAbout The Medicines Company\nThe Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. The Company’s mission is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. The Company is headquartered in Parsippany, New Jersey.\nView source version on businesswire.com : https://www.businesswire.com/news/home/20180327006435/en/\nInvestor Relations\nThe Medicines Company\nKrishna Gorti, M.D.\nVice President, Investor Relations\n(973) 290-6122\nkrishna.gorti@themedco.com\nSource: The Medicines Company", "external_links": ["https://www.businesswire.com/news/home/20180327006435/en/"], "published": "2018-03-28T04:05:00.000+03:00", "crawled": "2018-03-28T06:39:53.021+03:00", "highlightTitle": ""}